Stockscreener 앱 받기
4.64
2.73%
-0.13
시간 외 거래:
4.73
0.09
+1.94%
전일 마감가:
$4.77
열려 있는:
$4.82
하루 거래량:
90,189
Relative Volume:
0.74
시가총액:
$14.81M
수익:
-
순이익/손실:
$-37.75M
주가수익비율:
-1.4277
EPS:
-3.25
순현금흐름:
$-30.91M
1주 성능:
-19.72%
1개월 성능:
-7.20%
6개월 성능:
+1,601%
1년 성능:
+120.95%
1일 변동 폭
$4.56
$4.88
1주일 범위
$4.56
$6.52
52주 변동 폭
$0.224
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
명칭
Cellectar Biosciences Inc
전화
(608) 441-8120
주소
100 CAMPUS DRIVE, FLORHAM PARK, NJ
CLRB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
4.64 | 15.23M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-05 | 재개 | Ladenburg Thalmann | Buy |
| 2020-07-01 | 개시 | Oppenheimer | Outperform |
| 2020-01-21 | 재개 | ROTH Capital | Buy |
| 2019-09-13 | 개시 | ROTH Capital | Buy |
| 2016-12-21 | 개시 | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc 주식(CLRB)의 최신 뉴스
Is Cellectar Biosciences Inc. meeting your algorithmic filter criteriaEarnings Overview Report & Weekly Watchlist of Top Performers - newser.com
What drives Cellectar Biosciences Inc stock priceLow Risk Investment Ideas & Free Record-Breaking Gains - earlytimes.in
Cellectar Biosciences raises $5.8 million through warrant exercise and new inducement warrants - Investing.com Canada
Cellectar Biosciences Raises $5.8M Through Warrant Exercise - TipRanks
Will Cellectar Biosciences Inc. price bounce be sustainable2025 Top Decliners & Daily Profit Focused Screening - newser.com
What technical models suggest about Cellectar Biosciences Inc.’s comebackEntry Point & High Conviction Trade Alerts - newser.com
Understanding Cellectar Biosciences Inc.’s price movementWeekly Investment Summary & AI Forecasted Entry and Exit Points - newser.com
Cellectar Biosciences Inc. stock prediction for this weekMarket Rally & Low Drawdown Investment Ideas - newser.com
Custom watchlist performance reports with Cellectar Biosciences Inc.CPI Data & Long-Term Growth Plans - newser.com
Analyzing net buyer seller activity in Cellectar Biosciences Inc.Quarterly Portfolio Report & Safe Investment Capital Preservation Plans - newser.com
Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally - MSN
Cellectar Biosciences (CLRB) Secures $5.8 Million Through Warran - GuruFocus
Cellectar Biosciences raises $5.8 million through warrant exercise - Investing.com
Cellectar Biosciences enters agreements to raise $5.8M - TipRanks
Cellectar Biosciences raises $5.8 million through warrant exercise By Investing.com - Investing.com Australia
Cellectar Biosciences, Inc. enters into agreements to raise $5.8 million - MarketScreener
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million - GlobeNewswire
$5.8M Raised: Cellectar Biosciences Secures Funding via Warrant Exercises to Advance CLR 121125 - Stock Titan
Cellectar’s cancer drug advances toward European approval By Investing.com - Investing.com Nigeria
Cellectar Biosciences Announces European Medicines Agency - GlobeNewswire
Cellectar Biosciences (CLRB) Receives Positive Feedback for EU M - GuruFocus
What margin trends mean for Cellectar Biosciences Inc. stockEarnings Recap Summary & Growth Focused Stock Pick Reports - newser.com
Cellectar’s cancer drug advances toward European approval - Investing.com
Cellectar Biosciences Stock Rises Over EMA's Advise On CMA Filing For Iopofosine I 131 - Nasdaq
Cellectar Biosciences (CLRB) Moves Toward European Market with Potential Cancer Treatment - GuruFocus
Cellectar wins EMA nod to seek conditional approval for iopofosine in rare blood cancer - MarketScreener
Cellectar Biosciences Plans Conditional Marketing Authorization Submission for Iopofosine I 131 as Treatment for Refractory Waldenstrom Macroglobulinemia in Europe by Early 2026 - Quiver Quantitative
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) - The Manila Times
Cellectar Biosciences Announces Iopofosine I 131 as A Treatment for Refractory (Post-Btki) Waldenstrom Macroglobulinemia (Wm) - MarketScreener
Is Cellectar Biosciences Inc. stock a safe haven assetSell Signal & Long-Term Safe Investment Ideas - newser.com
How Cellectar Biosciences Inc. stock benefits from tech adoption2025 Market Overview & Real-Time Volume Analysis - newser.com
How to forecast Cellectar Biosciences Inc. trends using time series2025 Geopolitical Influence & Long Hold Capital Preservation Plans - newser.com
Can Cellectar Biosciences Inc. (NV4) stock hold up in economic slowdownTrade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com
What drives Cellectar Biosciences Inc NV4 stock priceIndustrial Stocks Review & Predict Price Movements With AI Precision - earlytimes.in
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer - GlobeNewswire
8.6-Month Survival: Cellectar's Novel Radiotherapy Shows Promise in Incurable Pediatric Brain Cancer Trial - Stock Titan
Can you recover from losses in Cellectar Biosciences Inc.Portfolio Gains Report & Safe Swing Trade Setups - newser.com
Cellectar Biosciences Inc (CLRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cellectar Biosciences Inc 주식 (CLRB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Longcor Jarrod | Chief Operating Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
12,768 |
| Kolean Chad J | Chief Financial Officer |
Jul 02 '25 |
Buy |
4.99 |
5,000 |
24,950 |
6,418 |
| Longcor Jarrod | Chief Operating Officer |
Jan 10 '25 |
Buy |
0.28 |
30,000 |
8,400 |
83,141 |
5.74%
자본화:
|
볼륨(24시간):